Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice

Journal of Infectious Diseases

Volumn 217, Issue 6, 2018, Pages 916-925

  Van Lieshout, Laura P ^a   Soule, Geoff ^b   Sorensen, Debra ^d   Frost, Kathy L ^d   He, Shihua ^b   Tierney, Kevin ^b   Safronetz, David ^b,d   Booth, Stephanie A ^c   Kobinger, Gary P ^d,e   Qiu, Xiangguo ^b,d   Wootton, Sarah K ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Zoonotic Diseases and Special Pathogens Program   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

Adeno associated virus; Ebola virus; Hemorrhagic fever; Neutralizing antibody; Vaccine; Vectored immunoprophylaxis; ZMapp

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G4; MONOCLONAL ANTIBODY 5D2; MONOCLONAL ANTIBODY 7C9; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLAVIRUS; GENE TRANSFER; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME TO TREATMENT; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DEPENDOPARVOVIRUS; EBOLA HEMORRHAGIC FEVER; IMMUNOLOGY; PASSIVE IMMUNIZATION; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DEPENDOVIRUS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 85042940751     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix644     Document Type: Article

References (50)

1. Spengler JR, Ervin ED, Towner JS, Rollin PE, Nichol ST. Perspectives on West Africa Ebola virus disease outbreak, 2013-2016. Emerg Infect Dis 2016; 22:956-63.
2. Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ 2017; 95:235-7.
3. Qiu X, Kobinger GP. Antibody therapy for Ebola: Is the tide turning around? Hum Vaccin Immunother 2014; 10.
4. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(Suppl 1):S18-23.
5. Qiu X, Wong G, Fernando L, et al. mAbs and Ad-Vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013; 5:207ra143.
6. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034-9.
7. Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013; 5:199ra13.
8. Qiu X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81.
9. Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012; 7:e36192.
10. Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109:18030-5.
11. Qiu X, Wong G, Fernando L, et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J Virol 2013; 87:7754-7.
12. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013; 110:1893-8.
13. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:158ra46.
14. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, Jones SM. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011; 141:218-27.
15. Audet J, Wong G, Wang H, et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 2014; 4:6881.
16. Fauci AS. Ebola-underscoring the global disparities in health care resources. N Engl J Med 2014; 371:1084-6.
17. Tran EE, Nelson EA, Bonagiri P, et al. Mapping of Ebolavirus neutralization by monoclonal antibodies in the zmapp cocktail using cryo-electron tomography and studies of cellular entry. J Virol 2016; 90:7618-27.
18. Qiu X, Fernando L, Melito PL, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 2012; 6:e1575.
19. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-4.
20. Cadogan M, Dalgleish AG. HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis 2008; 8:675-84.
21. Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adenoassociated virus (AAV) as a vector for gene therapy. BioDrugs 2017; 31:317-34.
22. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-55.
23. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-4.
24. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296-300.
25. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 2013; 31:647-52.
26. Limberis MP, Adam VS, Wong G, et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med 2013; 5:187ra72.
27. Limberis MP, Tretiakova A, Nambiar K, et al. Adenoassociated virus serotype 9-expressed ZMapp in mice confers protection against systemic and airway-acquired Ebola virus infection. J Infect Dis 2016; 214:1975-9.
28. Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002; 20:697-701.
29. Halbert CL, Allen JM, Chamberlain JS. AAV6 vector production and purification for muscle gene therapy. Methods Mol Biol 2018; 1687:257-66.
30. Aurnhammer C, Haase M, Muether N, et al. Universal realtime PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods 2012; 23:18-28.
31. Santry LA, Ingrao JC, Yu DL, et al. AAV vector distribution in the mouse respiratory tract following four different methods of administration. BMC Biotechnol 2017; 17:43.
32. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997; 239:206-16.
33. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
34. Qiao C, Zhang W, Yuan Z, et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010; 21:1343-8.
35. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009; 17:294-301.
36. Limberis MP, Racine T, Kobasa D, et al. Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9. Clin Vaccine Immunol 2013; 20:1836-7.
37. Deal C, Balazs AB, Espinosa DA, Zavala F, Baltimore D, Ketner G. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci U S A 2014; 111:12528-32.
38. Prasad KM, Smith RS, Xu Y, French BA. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J Gene Med 2011; 13:333-41.
39. Hu C, Lipshutz GS. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice. Gene Ther 2012; 19:1166-76.
40. Körbelin J, Dogbevia G, Michelfelder S, et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med 2016; 8:609-25.
41. Michelfelder S, Varadi K, Raupp C, et al. Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS One 2011; 6:e23101.
42. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008; 105:7827-32.
43. Greig JA, Peng H, Ohlstein J, et al. Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One 2014; 9:e112268.
44. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82:5887-911.
45. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
46. Davey RT, Dodd L, Proschan MA, et al. a randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375:1448-56.
47. Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 2001; 8:1281-90.
48. Flyak AI, Shen X, Murin CD, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection. Cell 2016; 164:392-405.
49. Zhang Q, Gui M, Niu X, et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep 2016; 6:25856.
50. Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 2016; 351:1339-42.